Branch retinal vein occlusion post severe acute respiratory syndrome coronavirus 2 vaccination

In this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer-BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of r...

Full description

Saved in:
Bibliographic Details
Published inTaiwan journal of ophthalmology Vol. 12; no. 2; pp. 202 - 205
Main Authors Tanaka, Hayato, Nagasato, Daisuke, Nakakura, Shunsuke, Nagasawa, Toshihiko, Wakuda, Hiroyuki, Kurusu, Akihiro, Mitamura, Yoshinori, Tabuchi, Hitoshi
Format Journal Article
LanguageEnglish
Published India Wolters Kluwer - Medknow Publications 01.04.2022
Medknow Publications and Media Pvt. Ltd
Wolters Kluwer - Medknow
Wolters Kluwer Medknow Publications
Subjects
adverse reactions
branch retinal vein occlusion
Case Report
coronavirus disease 2019
Coronaviruses
Health aspects
Pharmaceutical industry
Retinal diseases
RNA
Severe acute respiratory syndrome
Vaccination
United States
branch retinal vein occlusion
Adverse reactions
coronavirus disease 2019
vaccination
Online AccessGet full text

Cover

More Information
Summary:In this article, we report two patients who experienced the first onset of branch retinal vein occlusion (BRVO) 3 days after the administration of the BNT162b2 (Pfizer-BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccine. Case 1: A 50-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 2: A 56-year-old woman without any history of retinal disease developed vision loss in her right eye 3 days after receiving the first dose of the SARS-CoV-2 mRNA vaccine. Case 1: Temporal superior BRVO and secondary macular edema (ME) were observed in the patient's right eye. Her best-corrected visual acuity (BCVA) was 20/25. Case 2: Temporal inferior BRVO and secondary ME were observed in the patient's right eye. Her BCVA was 13/20. Case 1: Three doses of intravitreal ranibizumab (IVR) were administered. Case 2: Three doses of IVR were administered. Case 1: ME resolved and BCVA improved to 20/20. Case 2: ME resolved and BCVA improved to 20/20. Both the cases showed a possible association between the SARS-CoV-2 vaccination and the first onset of BRVO.
Bibliography:ObjectType-Case Study-2
SourceType-Scholarly Journals-1
ObjectType-Feature-4
content type line 23
ObjectType-Report-1
ObjectType-Article-3
ISSN:2211-5056
2211-5072
2211-5072
DOI:10.4103/tjo.tjo_24_22